Role of hypoxia in viability and endothelial differentiation potential of UC-MSCs and VEGF interference

Journal of Central South University (Medical Sciences)

Volumn 38, Issue 4, 2013, Pages 329-340

  Li, Peng ^a   Zhou, Changyong ^a   Yin, Lei ^a   Meng, Xianqin ^a   Zhang, Lina ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Apoptosis; Differentiation; Hypoxia; Mesenchymal stem cells; Proliferation; VEGF

Indexed keywords

PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; UMBILICAL CORD;

APOPTOSIS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; HUMANS; MESENCHYMAL STROMAL CELLS; PROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; UMBILICAL CORD; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878151009     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-7347.2013.04.001     Document Type: Article

References (42)

1. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells[J]. Science, 1999, 284(5411):143-147. (Pubitemid 29282067)
2. Ren G, Chen X, Dong F, et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues[J]. Stem Cells Transl Med, 2012, 1(1):51-58.
3. Batsali AK, Kastrinaki MC, Papadaki HA, et al. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications[J]. Curr Stem Cell Res Ther, 2013, 8(2):144-155.
4. Lee KD. Applications of mesenchymal stem cells: an updated review[J]. Chang Gung Med J, 2008, 31(3):228-236.
5. Harrop JS, Hashimoto R, Norvell D, et al. Evaluation of clinical experience using cell-based therapies in patients with spinal cord injury: a systematic review[J]. J Neurosurg Spine, 2012, 17(1):230-246.
6. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells[J]. Ann NY Acad Sci, 2009, 1176(9):101-117.
7. Wang D, Chen K, Du WT, et al. CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells[J]. Exp Cell Res, 2010, 316(15):2414-2423.
8. Shetty P, Cooper K, Viswanathan C. Comparison of proliferative and multilineage differentiation potentials of cord matrix, cord blood, and bone marrow mesenchymal stem cells[J]. Asian J Transfus Sci, 2010, 4(1):14-24.
9. Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population[J]. Stem Cells, 2008(26):591-599.
10. Li DR, Cai JH. Methods of isolation, expansion, differentiating induction and preservation of human umbilical cord mesenchymal stem cells[J]. Chin Med J, 2012, 125(24):4504-4510.
11. Chen MY, Lie PC, Li ZL, et al. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal steiji cells[J]. Exp Hematol, 2009, 37(5):629-640.
12. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord[J]. Stem Cells, 2004, 22(7):1330-1337.
13. Shi RZ, Li QP. Improving outcome of transplanted mesenchymal stem cells for ischemic heart disease[J]. Biochem Biophys Res Commun, 2008, 376(2):247-250.
14. Belmokhtar K, Bourguignon T, Worou ME, et al. Regeneration of three layers vascular wall by using BMP2-treated MSC involving HIF-la and Idl expressions throughJAK/STAT pathways[J]. Stem Cell Rev, 2011, 7(4):847-859.
15. Lavrentieva A, Majore L, Kasper C, et al. Effects of hypoxic culture conditions on umbilical cord-derived human mesenchymal stem cells[J]. Cell Commun Signal, 2010, 8(7):18.
16. Potier E, Ferreira E, Andriamanalijaona R, et al. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression[J]. Bone, 2007, 40(4):1078-1087. (Pubitemid 46386551)
17. Holzwarth C, Vaegler M, Gieseke F, et al. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells[J]. BMC Cell Biology, 2010, 11(1):11.
18. Oswald J, Boxberger S, Jorgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro[J]. Stem Cells, 2004, 22(3):377-384. (Pubitemid 38736621)
19. Gang EJ, Jeong JA, Han S, et al. In vitro endothelial potential of human UC blood-derived mesenchymal stem cells[J]. Cytotherapy, 2006, 8(3):215-227. (Pubitemid 43947788)
20. Pons J, Huang Y, Arakawa-Hoyt J, et al. VEGF improves survival of mesenchymal stem cells in infarcted hearts[J]. Biochem Biophys Res Commun, 2008, 376(2):419-422.
21. Zisa D, Shabbir A, Suzuki G, et al. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair[J]. Biochem Biophys Res Commun, 2009, 390(3):834-838.
22. Lu LL, Liu YJ, Yang SG, et al. isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials[J]. Haematologica, 2006, 91(8):1017-1026.
23. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8(4):315-317. (Pubitemid 44269669)
24. Short B, Brouard N, Occhiodoro-Scott T, et al. Mesenchymal stem cells[J]. Arch Med Res, 2003, 34(6):565-571.
25. Pikir BS, Susilowati H, Hendrianto E, et al. Reversin increase the plasticity of bone marrow-derived mesenchymal stem cell for generation of cardiomyocyte in vitro[J]. Acta Med Indones, 2012, 44(1):23-27.
26. Harrop JS, Hashimoto R, Norvell D, et al. Evaluation of clinical experience using cell-based therapies in patients with spinal cord injury: a systematic review[J].j Neurosurg Spine, 2012, 17(1):230-246.
27. Wolf D, Reinhard A, Krause U, et al. Stem cell therapy improves myocardial perfusion and cardiac synchronicity: new application for echocardiography[J]. J Am Soc Echocardiogr, 2007, 20(5):512-520. (Pubitemid 46678691)
28. Simpson DL, Boyd NL, Kaushal S, et al. Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair [J]. Biotechnol Bioeng, 2012, 109(1):274-283
29. Jackson WM, Nesti LJ, Tuan RS. Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells[J]. Stem Cells Transl Med, 2012, 1(1):44-50.
30. Zhang M, Methot D, Poppa V, et al. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies[J]. J Mol Cell Cardiol, 2001, 33(5):907-921. (Pubitemid 32545326)
31. Zhu W, Chen J, Cong X, et al. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells[J]. Stem Cells, 2006, 24(2):416-425. (Pubitemid 44464811)
32. Ren H, Cao Y, Zhao Q et al. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions[J]. Biochem Biophys Res Commun, 2006, 347(1):12-21. (Pubitemid 44040907)
33. KONG Xia, ZHENG Fei, GUO Lingyun, et al. VEGF promotes the proliferation of bone marrow derived mesenchymal stem cells through ERK1/2 signal pathway[J]. Journal of Experimental Hematology, 2010, 18(5):1292-1296.
34. Buravkova LB, Andreeva ER, Grigor'ev AI. The impact of oxygen tension in physiological regulation of human multipotent mesenchymal stromal cell functions[J]. Fiziol Cheloveka, 2012, 38(4):121-130.
35. Vieira HL, Alves PM, Vercelli A. Modulation of neuronal stem cell differentiation by hypoxia and reactive oxygen species[J]. Prog Neurobiol, 2011, 93(3):444-455.
36. Lin RZ, Wang TP, Hung RJ, et al. Tumor-induced endothelial cell apoptosis: roles of NAD (P) H oxidase-derived reactive oxygen species[J]. J Cell Physiol, 2011, 226(7):1750-1762.
37. Lendahl U, Lee KL, Yang H, et al. Generating specificity and diversity in the transcriptional response to hypoxia[J]. Nat Rev Genet, 2009, 10(12):821-832.
38. Dos Santos F, Andrade PZ, Boura JS, et al. Ex vivo expansion of human mesenchymal stem cells: a more effectivecell proliferation kinetics and metabolism under hypoxia[J]. J Cell Physiol, 2010, 223(1):27-35.
39. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6):669-676.
40. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation[J]. J Biol Chem, 1998, 273(46):30336-30343. (Pubitemid 28545503)
41. Song YH, Gehmert S, Sadat S, et al. VEGF is critical for spontaneous differentiation of stem cells into cardiomyocytes[J]. Biochem Biophys Res Commun, 2007, 354(4):999-1003- (Pubitemid 46216232)
42. Dai Y, Xu M, Wang Y, et al. HIF-lo induced-VEGF over expression in bone marrow stem cells protects cardiomyocytes against ischemia[J]. J Mol Cell Cardiol, 2007, 42(6):1036-1044. (Pubitemid 46829200)